Immune regeneration in irradiated mice is not impaired by the absence of DPP9 enzymatic activity

Margaret G. Gall1, Hui Emma Zhang1, Quintin Lee1, Christopher J. Jolly2, Geoffrey W. McCaughan1, Adam Cook1, Ben Roediger1 & Mark D. Gorrell1

The ubiquitous intracellular protease dipeptidyl peptidase 9 (DPP9) has roles in antigen presentation and B cell signaling. To investigate the importance of DPP9 in immune regeneration, primary and secondary chimeric mice were created in irradiated recipients using fetal liver cells and adult bone marrow cells, respectively, using wild-type (WT) and DPP9 gene-knockin (DPP9S729A) enzyme-inactive mice. Immune cell reconstitution was assessed at 6 and 16 weeks post-transplant. Primary chimeric mice successfully regenerated neutrophils, natural killer, T and B cells, irrespective of donor cell genotype. There were no significant differences in total myeloid cell or neutrophil numbers between DPP9-WT and DPP9S729A-reconstituted mice. In secondary chimeric mice, cells of DPP9S729A-origin cells displayed enhanced engraftment compared to WT. However, we observed no differences in myeloid or lymphoid lineage reconstitution between WT and DPP9S729A donors, indicating that hematopoietic stem cell (HSC) engraftment and self-renewal is not diminished by the absence of DPP9 enzymatic activity. This is the first report on transplantation of bone marrow cells that lack DPP9 enzymatic activity.

The ubiquitous intracellular post-proline serine protease dipeptidyl peptidase 9 (DPP9) belongs to the DPP4 gene family, which includes four atypical serine proteases: DPP4, fibroblast activation protein (FAP), DPP8 and DPP9. DPP9 plays roles in both innate and adaptive immunity. DPP9 is extensively expressed throughout immunological tissues in vivo and within individual leukocyte subpopulations. DPP9 mRNA and protein is up-regulated in stimulated mouse splenocytes and in Jurkat T- and Raji B-cell lines. Endogenous DPP9 limits the presentation of an antigenic peptide, RU134–42, through cleaving this peptide. DPP9 causes Syk degradation and thus influences Syk signalling in B cells. Activation and proliferation of innate and adaptive immune cells is diminished in the absence of DPP9 enzymatic activity. Within monocytes and macrophages, basal DPP8 and DPP9 activity suppresses inflammasome activation through inhibition of pro-caspase-1 activation via NLRP-1. Thus, a variety of evidence supports multiple roles for DPP9 in the regulation of immune function.

We generated the first gene DPP9 knock-in (DPP9S729A) mouse that has a single serine-to-alanine point mutation at the enzyme active site (S729A). Unlike mice deficient in any other protease of this gene family, homozygote DPP9 deficiency is neonate lethal. DPP9 is closely related to the extracellular protease DPP4 (CD26) and fibroblast activation protein (FAP). DPP4 is expressed by immune cells of both the myeloid and lymphoid lineages. Genetic or pharmacologic ablation of DPP4 improves bone marrow engraftment. We found that FAP expression does not influence the proportions of CD4+ and CD8+ T cells, B cells, dendritic cells and neutrophils in the thymus, lymph node or spleen in healthy adult mice. Whether the absence of DPP9 enzymatic activity affects short-term and long-term repopulation of immune cells of the lymphoid or myeloid lineages is underexplored.

Hematopoiesis is critically dependent upon hematopoietic stem cells (HSC). HSC migrate into the fetal liver between embryonic days (ED) 11 and 12 whereupon their numbers expand substantially. Between ED 13.5 and 14.5, the fetal liver contains large numbers of hematopoietic foci with erythropoiesis constituting a major part of their activity but also with capacity for myelopoiesis and lymphopoiesis. A successful short-term primary engraftment (30 to 60 days) can provide confirmation that the progenitor cell pool is intact and that all

1Centenary Institute, The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia.
2Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, 2052, Australia. Margaret G. Gall and Hui Emma Zhang contributed equally. Correspondence and requests for materials should be addressed to M.D.G. (email: m.gorrell@centenary.usyd.edu.au)
myeloid and lymphoid cell types are present and, in the long term (4 months), whether the reconstituted HSC are functional26–28. However, even successful long-term engraftment in a primary transplant recipient does not rule out defects in self-renewal or proliferation capability. Hence, a further serial transplant is often undertaken in chimera studies to demonstrate intact HSC engraftment and renewal27.

Post-transplant, identifying the progeny of the transplanted HSC is important to ascertain the effectiveness of the original graft and the properties of the regenerating immune system. The most commonly used method to achieve this is through the CD45 allelic model, where genetic differences in CD45 (CD45.1 and CD45.2) between donor and recipient mouse strains enable donor-derived cells to be traced by flow cytometry26,29.

Neutrophils and macrophages are the first cell types to recover after combined myelo-ablative irradiation and fetal liver or adult bone marrow cell transplant. These cells appear in the first few days after transplant, followed closely by B cells. Platelets and red blood cell lineages are present in the peripheral circulation at one to two weeks post-irradiation27. A small proportion of host T cells resist the effects of irradiation and expand in the post-irradiated environment, and can be detected within three weeks of transplant, while donor T cells usually become detectable 4 to 5 weeks after transplantation29.

Very recently, an independent study found that ED 17.5 fetal liver-derived hematopoietic stem cells from a similar DPP9S729A mouse16,17 are able to fully reconstitute immune cell subsets 6 weeks after transplant in competitive mixed chimeras30. Here, we have explored the role of DPP9 enzyme activity in immune cell development through the creation of two sequential chimeras using ED 13.5 to 14.5 fetal liver cells and using adult bone marrow cells of WT and DPP9S729A origin. Both short-term (6 weeks) and long-term (4 months) hematopoietic regeneration were analyzed.

Results

Hematopoietic stem cells in the fetal liver are unaltered by DPP9 genotype. Fetal liver cells were used as donor cells for primary bone marrow reconstitution chimeras because DPP9S729A mice die within 24 h of birth15–17, precluding the availability of an adult source of DPP9-defective HSC. Prior to chimera experiments, fetal liver cells deficient in DPP9 enzymatic activity were analyzed for viability and the phenotypic content of stem and progenitor cells, which are necessary for immune regeneration. At this developmental stage the majority of haematopoietic cells are committed to the erythroid lineage, as indicated by TER119 reactivity31,32, while the remaining cells predominantly express the myeloid-associated marker CD11b33. Fetal liver cells were harvested at ED13.5–14.5 and stained with antibodies against TER-119 and CD11b to identify erythroid and myeloid cells, respectively. Prior studies have shown that the ratio of TER-119+ to CD11b+ cells is indicative of the hematopoietic lineage of the cell27. Our results showed that the ratio of TER-119+ to CD11b+ cells was comparable between DPP9-WT and DPP9S729A fetal liver cells (Fig. 1). This data analysis excluded red blood cells, but data analysis that included red blood cells generated similar outcomes (Supplementary Fig. 1).

DPP9S729A fetal liver cells reconstitute the immune system of irradiated mice. Primary chimeras were generated using fetal liver cells from DPP9-WT and DPP9S729A mice. Peripheral blood was taken at 6
and 16 weeks post-transplantation for flow cytometry analyses of peripheral blood leukocytes, representative of short-term and long-term immune compartment regeneration, respectively.

**Donor cell survival and hematopoietic replenishment in primary chimeric mice.** Mice transplanted with DPP9-WT or DPP9S729A fetal liver cells showed no significant differences in either mean weight or mean percentage weight change throughout the experimental period (Supplementary Fig. 2). The replenishment by donor-derived cells in peripheral blood was examined by distinguishing the CD45 alleles in the recipient mice. The proportion of residual recipient cells (CD45.1+) present at 6 weeks post-transplantation was less than 7% of total peripheral blood leukocytes (Fig. 2), indicating that the donor cells (CD45.2+) survived the engraftment procedure and that the fetal liver cell transplant conferred a sufficiently effective donor graft to ensure hematopoietic cell reconstitution. At 16 weeks post-transplantation, the residual recipient cells had fallen to ~2% (Fig. 2), suggesting effective long-term engraftment by the donor cells. No statistical difference was seen between DPP9-WT and DPP9S729A donor cells at either 6 or 16 weeks post-transplantation. Thus, fetal liver cells carrying the DPP9S729A mutant allele were not impaired in their ability to engraft in irradiated congenic hosts.

**Identification of myeloid cell types in primary chimeric mice.** To examine the development and repopulation of hematopoietic lineages, the major myeloid and lymphoid cell types were analyzed. Comparison was made between DPP9-WT-origin and DPP9S729A-origin chimeras as well as normal peripheral blood leukocytes data for C57BL/6 mice. Here we assessed two major lineages: Ly6G+ neutrophils and CD3−CD19−NK1.1−Ly6G−CD11b+ myeloid cells (which are predominantly monocytes; data not shown). There were no significant differences observed between the WT and DPP9S729A cell-origin recipient mice for either time-point for either total myeloid cells or neutrophils (Fig. 3a), suggesting that carrying the mutant DPP9 allele does not significantly alter hematopoietic regeneration in primary chimeric mice.

There was a clear decrease in myeloid cells between 6 and 16 weeks post-transplantation (Fig. 3a). This decrease was similar in both genotype-origins, and is consistent with changes that are known to occur between short-term and long-term regeneration after irradiation and donor engraftment. By 16 weeks, myeloid cell levels were comparable to those found in normal mouse peripheral blood. Neutrophils normally represent the largest percentage of myeloid cells, at approximately 30% in mouse. Neutrophils of the primary chimera were ~21% at 6 weeks and decreased to ~14% at 16 weeks post-transplantation, with no significant difference between different genotype-origin groups (Fig. 3a).

**Identification of lymphoid cell types in primary chimeric mice.** In these analyses, we assessed the major lymphoid lineages, namely CD3+ T cells, CD19+ B cells, and NK1.1+ natural killer (NK) cells. NK cells, which contribute to the early detection of virus-infected and cancer cells, are important for defense against pathogens and regain normal cell numbers and function within a month of transplantation. In the primary chimeric mice, no significant difference in NK cell numbers was observed between different genotype-origin groups or between 6 and 16 weeks post-transplantation (Fig. 3b). These data suggest that once re-established in the peripheral blood, NK cell numbers were stable.

As reappearance of B cells is an early event occurring in the first few days after engraftment, the percentage of total B cells amongst the total lymphoid donor cells was expected to have reached a stable level by 6 weeks post-transplantation. This was the case for peripheral blood leukocytes at 6 weeks, although recovery in B cell numbers in the DPP9S729A-origin cells might have been slower than WT-origin cells (p = 0.065, Fig. 3b). At 16 weeks post-transplantation, the B cell numbers for both genotype-origin groups of mice were similar (Fig. 3b) and consistent with normal peripheral blood B cell percentages.
Residual T cells of recipient origin, which is the cell type most resistant to irradiation, can be readily detectable within the first three weeks. Donor-derived T cells become readily detectable 4 to 5 weeks post-transplantation. Since the primary chimeric mice received a lethal dose of myelo-ablative radiation, few residual recipient T cells were expected to survive. Concordantly, few donor T cells were detected 6 weeks post-transplantation (Fig. 3b). T cell numbers greatly increased over time, reaching ~10% of peripheral blood leukocytes at 16 weeks post-transplantation. As T cells comprise about 20% of peripheral blood leukocytes in normal mice, full reconstitution of the T cell compartment was perhaps not attained at 16 weeks post-transplantation in any of the mice. No significant difference in T cell numbers was observed between the WT and DPP9S729A cell-origin recipient mice.

Secondary chimeric mice of DPP9S729A-origin displayed an enhanced engraftment ability and an unimpaired capacity for self-renewal and proliferation. Successful long-term engraftment in a primary cell transplant recipient does not rule out defects in self-renewal capability. Hence, further serial transplants are often undertaken in studies of chimeras, in order to detect defects in HSC self-renewal capacity and the capacity for proliferation. Therefore, a second set of chimeric mice was generated, in which irradiated WT hosts received BM cells from primary chimeric mice along with BM cells from congenic PTPRCA mice as competitor cells. As the result of the secondary engraftment was unknown before commencement of the experiment,
competing donor cells and sub-lethal recipient irradiation were used to ensure successful cellular engraftment, immune regeneration and survival of the recipient mice.

Both mouse groups, which respectively received BM from the DPP9-WT-origin and DPP9S729A-origin primary chimeric mice, showed a similar pattern of weight loss and gain throughout 13 weeks of weight monitoring (Supplementary Fig. 3). Return to start weight after initial weight loss was achieved in a much shorter time frame (about 2 weeks post-transplantation) than for the primary chimeric mice (4–5 weeks post-transplantation). This is consistent with the sub-lethal irradiation dose administered to the secondary mice compared to the higher-dose, lethal myelo-ablative treatment of the primary mice.

**Donor cell survival and replenishment in secondary chimeric mice.** Irradiated mice were transplanted with DPP9S729A-origin and DPP9-WT-origin primary chimeric mouse BM cells along with CD45.1+ Ptprcα adult BM cells at a ratio of 40:60 (donor:competitor). As both competitor cells and recipient cells carried the CD45.1 allele, it was not possible to differentiate between these two sources of cells. Donor cells, however, all carried the CD45.2 allele and so could be clearly identified.

At both 6 and 16 weeks post-transplantation, the ratio of donor cells to competitor cells in WT-origin mice was 20:80 where the 80% includes residual recipient cells that survived irradiation (Fig. 4a). This shows a dominance of competitor and residual recipient cells over donor cells, possibly due to increased numbers of residual recipient cells after sub-lethal irradiation. Interestingly, for the DPP9S729A-origin groups, at both time-points, the ratio of donor to competitor (with residual recipient) cells was more closely aligned to the original transplanted cell ratio (40:60, Fig. 4a), suggesting that the DPP9S729A-origin donor cells had an enhanced engraftment ability. The ratio of donor to competitor cells did not alter between 6 and 16 weeks post-transplantation. Proportions

---

**Figure 4.** Secondary chimeric mice: Proportions of donor and residual recipient cells. Irradiated mice were transplanted with DPP9S729A or DPP9-WT adult bone marrow cells along with CD45.1+ Ptprcα adult BM cells at a ratio of 40:60 (donor:competitor). (a) The WT-origin group displayed a bias towards competitor cells over donor cells, whereas the DPP9S729A-origin group displayed no bias. All groups had a shortfall below 100% (dotted line), which represented outlier competitor cells and residual recipient cells that were gated out during analysis. Mean, SD and individual data. Significance; ****p < 0.0001. (b) Proportions of leukocyte subpopulations for each mouse. WT-origin n = 9, DPP9S729A-origin n = 10, at 6 weeks post-transplantation.
of individual cell populations are presented for each mouse at 6 weeks post-transplantation (Fig. 4b). Increased proportions of DPP9S729A-origin cells occurred across all lineages, suggesting better engraftment of HSC rather than improved competition by specific cell subsets.

**Identification of myeloid cell phenotypes in secondary chimeric mice.** No differences in myeloid cell populations were observed between WT-origin and DPP9S729A-origin groups, at 6 or 16 weeks post-transplantation (Fig. 5a). In a similar pattern to that seen in the primary chimeric mice, myeloid cell percentages showed a significant reduction from 6 to 16 weeks post-transplantation (Fig. 5a). Myeloid cell percentages at 6 weeks were reduced in the secondary chimera (~23%) compared to the primary chimera (~40%). Perhaps associated with this, the reduction in myeloid cell percentages at 16 weeks was less pronounced in the secondary than in the primary chimera. Similar to the primary chimera, approximately 60% of myeloid cells in each genotype were neutrophils at 6-weeks post-transplantation (Fig. 5a). At 16 weeks, however, this proportion was approximately 50% for each genotype, and this difference was significant for DPP9S729A-origin cells. Perhaps at 16 weeks there was a less intense irradiation-induced inflammatory response in the secondary compared to the primary chimera, or a more rapid resolution of that response, such that at 16 weeks the myeloid cell compartment was normalised from a neutrophil-biased state to encompass other granulocyte cell types.

**Identification of lymphoid cell phenotypes in secondary chimeric mice.** In secondary chimeric mice, the main lymphoid lineage cell subsets were present and were not significantly different in abundance between genotypes (Fig. 5b). As with the primary chimera, the B cell percentages were consistent with those normally observed in mouse peripheral blood leukocytes. In contrast to the primary chimeric mice, T cell percentages were approximately 11% at both 6 and 16 weeks post-transplantation in each chimera. This was less than the expected level of 20% T cells in peripheral blood leukocytes.

Considering the overall peripheral blood leukocytes of both myeloid and lymphoid lineage, the trend in the primary chimeric mice from 6 to 16-weeks post-transplant was towards a greater proportion of lymphoid
cells (Fig. 6a). This is consistent with a change from unlimited self-renewal ability by HSC towards a limited self-renewal ability as the regenerating immune system changes from short term to long term reconstitution. For the secondary chimeras, the peripheral blood leukocytes of both myeloid and lymphoid lineages were similar at 6 and 16 weeks post-transplant, with a strong bias towards the lymphoid lineages (Fig. 6b).

Discussion

We created chimeric mice using fetal and adult donor cells with both normal and absent DPP9 enzymatic activity. We showed that a lack of DPP9 enzymatic activity in HSC does not impair their ability to engraft in irradiated mice or to repopulate all major immune cell types in the regenerated immune system in primary or secondary chimeras. Interestingly, secondary chimeric mice were efficiently engrafted by blood immune cell precursors lacking DPP9 enzymatic activity.

Fetal liver cells of DPP9-WT and DPP9 S729A origin consisted of the same proportions of erythroid and non-erythroid lineage cells. This provided a common starting point for creation of the chimeric mice and for assessment and quantification of HSC numbers and functionality.

Our data broadly concord with data from an independently-derived DPP9 S729A mouse. That study examined only primary chimeras and only at 6 weeks and used ED 17.5 rather than ED 13.5 fetal liver. Importantly, the data from both that study and our study are consistent with current knowledge of normal engraftment by fetal liver cells and so equally suggest that lacking DPP9 does not impair engraftment.

The reconstitution of the primary chimeric mice was very high at both 6 and 16 weeks post-transplant, with only small percentages of residual recipient cells present. Taken together, there was no detectable impairment in the ability of DPP9 S729A HSC to engraft in the primary chimera. For the secondary chimeric mice, with an original transplant ratio of 40:60 of donor to competitor cells, the WT-origin group had a higher ratio (20:80) whilst the DPP9 S729A-origin group had a similar ratio to that of the original transplant. Thus, the DPP9 S729A-origin donor cells

Figure 6. Enumeration of donor peripheral blood leukocytes of primary and secondary chimeric mice. Phenotypic analyses of total peripheral blood leukocytes (PBL) of donor origin. Between 6 and 16 weeks after fetal liver cell transplant, both WT-origin and DPP9 S729A-origin mice increased the proportion of lymphoid lineage cells in PBL (a). The proportions of lymphoid and myeloid lineage cells were comparable between 6 and 16 weeks after bone marrow cell transplant of WT-origin or DPP9 S729A-origin cells (b).
may possess an enhanced engraftment ability in the secondary chimera. Ablation of the DPP9 – related enzyme DPP4 enhances HSC engraftment in irradiated mice21, so this might be a general property of inhibitors of this enzyme family.

Having confirmed effective engraftment of donor cells, we then determined the contribution of hematopoietic cell lineages to the development and repopulation of the reconstituting immune system. At 6 and 16 weeks post-transplantation, in both the primary and secondary chimeric mice, all myeloid and lymphoid cell types considered in this study were present in both genotype-origin groups. Therefore, the progenitor cell pool was intact and both the primary and secondary HSC showed no defect in self-renewal or proliferation capability with the absence of DPP9 enzymatic activity.

The total myeloid lineage cell numbers did not differ with genotype. NK cell numbers were stable regardless of genotype. T cell reconstitution showed no difference between genotypes.

B cells were present at comparable levels in the primary and secondary chimeras. However, in the primary chimeric mice, fewer B cells in the DPP9S729A-origin group were seen compared to the WT-origin group at 6 weeks but not at 16 weeks, which might reflect a delay in B cell re-establishment by cells lacking DPP9 enzyme activity. Taken together, these results indicate that the lack of DPP9 enzymatic activity in hematopoietic cell lineages affect the generation of granulocyte subsets and B cells but not NK cells or T cells. DPP9 inhibition stabilizes Syk, thereby modulating Syk signaling in B cells. Thus, DPP9 enzyme activity might have a role in B cell function that influences differentiation and/or proliferation in the absence of antigen stimulation.

In summary, this is the first report exploring the role of DPP9 enzyme activity in immune cell development through the creation of two sequential chimeras using both fetal liver cells and adult bone marrow cells that lack DPP9 enzymatic activity. This work contributes to the understanding of the DPP9 protease in biological systems.

Materials and Methods

Ethics statement. All animal handling and experimental procedures were approved by Sydney Local Health District Animal Welfare Committee under ethics protocol 2013/017 (K75/5-2012/3/5754), and conducted in accordance with all applicable laws and guidelines. A body scoring system was used for each mouse of posture, activity and gait, breathing, hydration, the presence of abnormal excreta, body condition and body weight as compared to the baseline weight. A weight loss of greater than 15% compared to original weight triggered euthanasia of the mouse.

Mice. Mice were maintained in the Centenary Institute animal facility under specific pathogen free conditions and exposed to a 12 h light-dark cycle. C57BL/6J and PTPRCA mice were purchased from either Animal Resource Centre (Perth, WA, Australia) or Australian BioResources (Moss Vale, NSW, Australia). Mice were housed 4–6 mice per cage with ad libitum access to rodent chow (Speciality Feeds, Perth, Western Australia) and water and entered experiments more than one week after any transport. All the mice used for chimera experiments were at least 8 weeks old before irradiation.

The DPP9S729A mouse strain has been described15. All embryos required for fetal liver cells were obtained from pregnant females where pregnancy resulted from timed mating of DPP9 heterozygous intercrosses. For mating, single females were placed in the male home cage for 12h then checked for the presence of a vaginal plug as an indicator of mating prior to separation from the male. The time of separation of female and male was designated ED 0.5. Females were weighed at ED 0.5 and weighed daily from ED 4.5 until ED 13. Pregnancy was suggested by weight gain greater than non-pregnant between ED 7.5 and ED 13.549.

Generation of fetal liver chimeras. Primary chimeras were generated using donor-derived fetal liver cells48. Liver cells from embryonic mouse livers at ED13.5 – ED14.5 from DPP9S729A and DPP9-WT (DPP9-WT) pups were excised and mashed through a 70μm sieve into liver cell buffer (1% Glutamax, 2% Penistrep, 10% FCS in Dulbecco’s Modified Eagle’s Medium). The cell suspension was centrifuged at 2000 rpm for 5 min and the pellet resuspended in cell freezing solution (10% DMSO in FCS). It was necessary to store liver cells by freezing until genotyping results confirmed. When thawing, cell suspension was centrifuged at 2000 rpm for 7 min and the pellet resuspended in 10mL liver cell buffer. After standing at room temperature for 30 min to release the maximum amount of DMSO, the cell suspension was centrifuged at 4 °C to 2000 rpm for 7 min and resuspended in 400 μL of Hank’s balance salt solution (HBSS) for injection. Eighteen 10 week-old male PTPRCA mice (carrying the CD45.1 allele) received two doses of a 600 rad exposure (at a dose rate of 110 rad per minute) of myelo-ablative radiation using a Gammacell® 40 Exacter Low Dose-Rate Research Irradiator (MDS Nordion Inc. Ontario, Canada) administered 4 h apart as previously described40. For fetal liver cell transplant, 2 × 10⁶ cells at a volume of 200 μL per recipient mouse was injected via the lateral tail vein into recipient mice 3–4 h after irradiation. Post-transplantation, mice were provided with antibiotic in water for 14 days and monitored daily.

Generation of bone marrow chimeras. Bone marrow (BM) was prepared and transplanted as previously40. Secondary chimeras were produced by transferring regenerated BM donor cells from adult primary chimeric mice into new irradiated recipient mice. Nineteen 10 week-old male PTPRCA mice received one dose of a 750 rad exposure of myelo-ablative radiation as described above. The donors were two healthy DPP9S729A-origin primary chimeric mice and two DPP9-WT-origin primary chimeric mice (all carrying the CD45.2 allele). Each pair of selected donor mice had shared a cage but the chimerism in each mouse was produced with a different batch of fetal liver cells. BM cells from these four mice, along with two control male PTPRCA mice, were harvested. BM were released from the femur, tibia and fibula, rinsed and filtered through a 70 μm filter. Cell suspension was centrifuged at 300 × g for 5 min at 4 °C and the pellet re-suspended in HBSS. For bone marrow transplant, 6.7 × 10⁶ primary chimeric bone marrow cells and 10 × 10⁶ competitor bone marrow cells (carrying the CD45.1 allele) from PTPRCA mice (ratio of donor: competitor = 40%: 60%) at a volume
Table 1. Antibodies and their target cell types.

| Fluorochrome-Antibody | Synonym/clone | Target cell | Dilution used | Source catalog # |
|------------------------|--------------|-------------|---------------|-----------------|
| APC-TER-119            | TER-119      | Leukocytes of erythroid lineage | 1:250          | BD Biosciences, #557909 |
| BV2CD19                | I23          | B cells     | 1:200         | BD Biosciences #563557 |
| BV421 CD3e             | 145-2C11     | T cells, NK cells | 1:250          | BD Biosciences #562600 |
| V500 CD45.2            | 104          | Leukocytes  | 1:250         | BD Biosciences #562129 |
| FITC CD11b             | M1/70        | Myeloid cells | 1:250          | BD Biosciences #557396 |
| PerCP-Cy5.5 CD45.1     | A20          | Leukocytes  | 1:250         | eBioscience #45-0453 |
| PE PK1.1               | PK136        | NK cells    | 1:250         | BD Biosciences #557391 |
| AF647 Ly6G             | IA8          | Neutrophils | 1:250         | Biolegend #127610 |
| APC-Cy7 CD8α           | 53–67        | T cells     | 1:250         | BD Biosciences #557654 |

of 200 μL per recipient mouse were injected via the lateral tail vein into recipient mice 3–4 h after irradiation. Post-transplantation, mice were provided with antibiotic water for 14 days and monitored daily.

Flow cytometry. For analysis of fetal liver cells, cell aliquots were thawed and red blood cells were lysed (8.26 g ammonium chloride, 1 g potassium bicarbonate and 0.037 g EDTA dissolved in 1 L of dH2O). After centrifugation and washing, cell pellet was resuspended in 200 μL of FACS wash. Then 100 μL of stain cocktail containing TER-119-APC and CD11b-FITC antibodies (Table 1) was added and incubated on ice for 1 h. For analysis of peripheral blood, 5–6 drops of blood from tail vein were collected into an Eppendorf containing 50 μL of 0.1 M EDTA. After red blood cell lysis, cells were pelleted and re-suspended in 200 μL FACS wash. Then 100 μL of stain cocktail containing a number of antibodies to identify immune cell populations represented in a reconstituted immune system (Table 1) was added and incubated on ice for 1 h. Just prior to flow analysis, cells were filtered and DAPI was added (100 ng/mL). Flow cytometry data were acquired using a BD LSR Fortessa cytometer (BD Biosciences) and subsequently analyzed with FlowJo 10 software (Treestar Inc., Ashland, OR, USA). Gating strategies are shown in Supplementary Figs 1 and 4. Data were then analyzed by non-parametric Mann-Whitney U test using GraphPad Prism (GraphPad v. 9.9, San Diego, CA, USA).

Data Availability

The datasets generated during the current study are available from the corresponding author upon reasonable request.

References

1. Abbott, C. A. et al. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur. J. Biochem. 267, 6140–6150 (2000).
2. Ajami, K., Abbott, C. A., McLaughlin, G. W. & Gorrell, M. D. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. BBA Gene Structure Expression 1679, 18–28, https://doi.org/10.1016/j.bbagsep.2004.03.010 (2004).
3. Yu, D. M. T. et al. The in vivo expression of dipeptidyl peptidases 8 and 9. J. Histochem. Cytochem. 57, 1025–1040, https://doi.org/10.1369/jhc.2009.935760 (2009).
4. Lankas, G. et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 54, 2988–2994 (2005).
5. Maes, M.-B. et al. Dipeptidyl peptidase 8/9-like activity in human leukocytes. J. Leukoc. Biol. 81, 1252–1257 (2007).
6. Chowdhury, S., et al. Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver. World J. Gastroenterol. 19, 2883–2893, https://doi.org/10.3748/wjg.v19.i19.2883 (2013).
7. Zhang, H., Chen, Y., Keane, F. M. & Gorrell, M. D. Advances in understanding the expression and function of dipeptidyl peptidase 8 and 9. Mol. Cancer Res. 11, 1487–1496, https://doi.org/10.1158/1541-7786.mcr-13-0272 (2013).
8. Justa-Schuch, D. et al. DPP9 is a novel component of the N-end rule pathway targeting the tyrosine kinase Syk. eLife 5, e16370, https://doi.org/10.7554/elife.16370 (2016).
9. Waumans, Y. et al. The dipeptidyl peptidase 4, 8, and 9 in mouse monococytes and macrophages: DPP8/9 inhibition attenuates M1 macrophage activation in mice. Inflammation 39, 413–424, https://doi.org/10.1007/s10753-015-0263-5 (2016).
10. Geiss-Friedlander, R. et al. The cytoplasmic peptidase DPP9 is rate-limiting for degradation of proline-containing peptides. J. Biol. Chem. 284, 27211–27219, https://doi.org/10.1074/jbc.M109.041871 (2009).
11. Reinhold, D. et al. Role of dipeptidyl peptidase IV (DPPIV)-like enzymes in T lymphocyte activation: investigations in DPPIV/CD26 knockout mice. Clin. Chem. Lab. Med. 47, 268–274, https://doi.org/10.1515/CCLM.2009.062 (2009).
12. Waumans, Y., Baerts, L., Keoh, K., Lambeir, A.-M. & De Meester, I. The dipeptidyl peptidase 8/9 family, prolyl oligopeptidase and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis. Front. Immunol. 6, 387–405, https://doi.org/10.3389/fimmu.2015.00387 (2015).
13. Okondo, M. C. et al. DPP8 and DPP9 inhibition induces pro-caspase-1-dependent macrocyte and macrophage pyroptosis. Nat. Chem. Biol. 13, 46–53, https://doi.org/10.1038/nchembio.2229 (2017).
14. Okondo, M. C. et al. Inhibition of DPP9/8 activates the NLRP1b inflammasome. Cell Chem. Biol. 25, 262–267, https://doi.org/10.1016/j.chembiol.2017.12.013 (2018).
15. Gall, M. G. et al. Targeted inactivation of Dipeptidyl Peptidase 9 enzyme activity causes mouse neonate lethality. PLoS ONE 8, e0073878, https://doi.org/10.1371/journal.pone.0073878 (2013).
16. Kim, M. et al. DPP9 enzyme activity controls survival of mouse migratory tongue muscle progenitors and its absence leads to neonatal lethality due to suckling defect. Dev. Biol. 431, 297–308, https://doi.org/10.1016/j.ydbio.2017.09.001 (2017).
17. Zhang, H. E., Gall, M. G. & Gorrell, M. D. Letter to Editor. Dev. Biol. 439, 1, https://doi.org/10.1016/j.ydbio.2017.12.009 (2018).
40. Shklovskaya, E.
39. Mader, S. L., Libal, N. L., Pritchett-Corning, K., Yang, R. & Murphy, S. J. Refining timed pregnancies in two strains of genetically engineered mice. **Nat. Rev. Genet.** **15**, 18049–18054, https://doi.org/10.1073/pnas.1110076108 (2011).

18. Ross, B. et al. Structures and mechanism of dipeptidyl peptidases 8 and 9, important players in cellular homeostasis and cancer. **Proc. Natl Acad. Sci. USA** **115**, E1437–E1445, https://doi.org/10.1073/pnas.1717565115 (2018).

19. Cook, S. et al. Differential chemokine receptor expression and usage by pre-cDC1 and pre-cDC2. **Immunol. Cell Biol.** **96**, 1131–1139, https://doi.org/10.1111/inc.12186 (2018).

20. Klemann, C., Wagner, L., Stephan, M. & von Horsten, S. Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system. **m. Clin. Exp. Immunol.** **185**, 1–21, https://doi.org/10.1111/ice.12781 (2016).

21. Broumeyer, H. E. et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. **Nat. Med.** **18**, 1786–1796, https://doi.org/10.1038/nm.2991 (2012).

22. Tan, S.-Y., Chowdhury, S., Polak, N., Gorrell, M. D. & Weninger, W. Fibroblast activation protein is dispensable in the anti-influenza immune response in mice. **PLoS ONE** **12**, e0171194, https://doi.org/10.1371/journal.pone.0171194 (2017).

23. Ema, H. & Nakauchi, H. Expansion of hematopoietic stem cells in the developing liver of a mouse embryo. **Hematopoiesis** **95**, 2284–2288 (2000).

24. Mikkola, H. K. & Orkin, S. H. The journey of developing hematopoietic stem cells is dispensable for mouse hematopoiesis. **Immunol. Lett.** **198**, 60–65, https://doi.org/10.1016/j.imlet.2018.04.008 (2018).

25. Kina, T. et al. The monoclonal antibody TER-119 recognizes a molecule associated with glycoporphin A and specifically marks the late stages of murine erythroid lineage. **Br. J. Haematol.** **109**, 280–287 (2000).

26. Kim, I., He, S., Yilmaz, Ö. H., Kiel, M. J. & Morrison, S. J. Enhanced purification of fetal liver hematopoietic stem cells using SLAM family receptors. **Blood** **108**, 737–744, https://doi.org/10.1182/blood-2005-10-4136 (2005).

27. Babovic, S. & Eaves, C. J. Hierarchical organization of fetal and adult hematopoietic stem cell populations. **Exp. Cell Res.** **329**, 185–191, https://doi.org/10.1016/j.yexcr.2014.08.005 (2014).

28. Auletta, J. J., Devecchio, J. L., Ferrara, J. L. M. & Heinzel, F. P. Distinct phases in recovery of reconstituted innate cellular-mediated immunity after murine syngeneic bone marrow transplantation. **Biol. Blood Marrow Transplant.** **10**, 834–847, https://doi.org/10.1016/j.bmt.2004.08.003 (2004).

29. Spangrude, G. J. In **Carr. Protoc. Immunol.** (John Wiley & Sons, Inc., 2001).

30. Kim, M. et al. DPP9 enzymatic activity in hematopoietic cells is dispensable for mouse hematopoiesis. **Immunol. Lett.** **198**, 60–65, https://doi.org/10.1016/j.imlet.2018.04.008 (2018).

31. Chen, J. & Harrison, D. E. Quantitative trait loci regulating relative lymphocyte proportions in mouse peripheral blood. **Blood** **99**, 561–566 (2002).

32. Auletta, J. J., Devecchio, J. L., Ferrara, J. L. M. & Heinzel, F. P. Distinct phases in recovery of reconstituted innate cellular-mediated immunity after murine syngeneic bone marrow transplantation. **Biol. Blood Marrow Transplant.** **10**, 834–847, https://doi.org/10.1016/j.bmt.2004.08.003 (2004).

33. Langerhans cells are precommitted to immune tolerance induction. **Proc. Natl Acad. Sci. USA** **104**, 5878–5882, https://doi.org/10.1073/pnas.070460104 (2007).

34. Anzai, H. K. In **Radiation Oncology: Radiobiological and Physiological Perspectives**: The boundary-zone between clinical radiotherapy and fundamental radiobiology and physiology Vol. 60 Developments in Oncology Ch. III.5, 247–290 (Springer Science + Business Media, 1990).

35. Sun, G., Li, X., Lu, L., Qian, T. & Wang, L. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. **Blood** **113**, 6342–6350, https://doi.org/10.1182/blood-2008-12-192054 (2009).

36. Mader, S. L., Libal, N. L., Pritchett-Corning, K., Yang, R. & Murphy, S. J. Defining the roles of the DPP9 enzyme. **Blood** **113**, 6342–6350, https://doi.org/10.1182/blood-2008-12-192054 (2009).

37. Kent, D. G. et al. Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential. **Blood** **113**, 6342–6350, https://doi.org/10.1182/blood-2008-12-192054 (2009).

38. Skhlovskaya, E. et al. Langerhans cells are precommitted to immune tolerance induction. **Proc. Natl. Acad. Sci. USA** **108**, 18049–18054, https://doi.org/10.1073/pnas.110076108 (2011).

Acknowledgements

This work was supported by the National Health and Medical Research Council of Australia Project Grant 512282 (MDG) and Program Grant 571408 (GWM), The Rebecca L. Cooper Medical Research Foundation, a University of Sydney Equipment Grant, Sydney Medical School Foundation/Francis M. Hooper Scholarship for Medical Research through the University of Sydney (MGG), and an Australian Postgraduate Award (HEZ). The authors thank Jeff Crosbie for mice irradiation. The authors acknowledge the animal facility and the flow cytometry facility at the Centenary Institute for the scientific and technical assistance.

Author Contributions

M.G.G. performed the majority of experiments and data analyses. A.C. designed experiments and contributed to some experiments. H.Z., Q.L., M.D.G., B.R., C.J. and G.M. contributed to data interpretation, data presentation and manuscript writing. M.D.G. and C.J. oversaw the laboratories in which these studies occurred.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-43739-w.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019